Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.Following an Independent Data Monitoring Committee recommendation and pre-specified interim analysis, SunRISe-2 was discontinued for not showing superiority versus chemoradiation.“We remain confident in the TARIS platform having over $5 billion potential,” ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 15, 2024, might help the stock move higher if these key numbers are better ...

文章核心观点 - 强生公司宣布终止针对肌肉浸润性膀胱癌(MIBC)患者的TAR-200疗法二期临床试验 [1] - 该决定是基于中期分析结果显示TAR-200疗法未能优于现有的化疗放疗治疗 [1] - 尽管遭遇此挫折,强生公司仍有信心获得FDA在2025年初批准TAR-200作为非肌肉浸润性膀胱癌(NMIBC)单药治疗的申请 [1] - 强生公司预计TAR-200平台的销售将超过50亿美元 [1] 行业概况 - 膀胱癌是老年人常见疾病,平均诊断年龄为70岁 [2] - 每年全球约有57万新发病例,其中25%为MIBC,20%高危NMIBC患者可能进展为MIBC [2] - MIBC预后较差,接受治疗5年总生存率为48%-70%,未接受治疗仅5% [2] 公司情况 - 强生公司于2019年通过收购TARIS Biomedical公司获得TARIS平台,包括TAR-200在内的技术 [2] - TAR-200是一种创新的膀胱内给药系统,能持续缓慢给药低剂量吉西他滨,该药物对多种膀胱癌有效 [2]

Johnson & Johnson (JNJ) will report its third-quarter earnings on Oct. 15. The Zacks Consensus Estimate for sales and earnings is pegged at $22.19 billion and $2.19 per share, respectively. The Zacks Consensus Estimate for JNJ’s earnings has declined from $10.07 per share to $10.00 per share for 2024 and from $10.63 per share to $10.62 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchJNJ's Earnings Surprise HistoryThe healthcare bellwether’s performance ha ...

Johnson & Johnson (JNJ) announced that it has discontinued the phase II field study, which evaluated the company’s investigational antiviral candidate mosnodenvir (formerly JNJ-1802) for the prevention of dengue virus in patients aged between 18 years and 65 years.JNJ decided to stop this study (NCT05201794) as part of the strategic reprioritization of its Communicable Diseases research and development (R&D) portfolio.Year to date, shares of JNJ have risen 2.3% compared with the industry’s growth of 18.5%.I ...

While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment. Get stock market alerts:Risk-Aversion and Risk-Averse StocksRisk-averse investors prioritize investments with lower potential returns and lower potential ...

These storied companies have a lot to offer different investors.Income stocks get their name because they provide dividend payments to your portfolio, expanding your returns and investment capital over time. Not only can income stocks boost your overall return on investment, but they can also be an excellent way to diversify the types of stocks you keep in your portfolio.If you're looking for income stocks to buy right now, here are two well-known names to consider for your list of potential investments.1. ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $160.50, reflecting a -0.42% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.17%. At the same time, the Dow lost 0.44%, and the tech-heavy Nasdaq lost 0.04%.The world's biggest maker of health care products's stock has dropped by 3.7% in the past month, exceeding the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 1.25%.The investment community will be paying close at ...

Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibilityNew indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint RARITAN, N.J., Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food an ...

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †.93% of patients become free from glasses at all distances.#4 ‡TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶JACKSONVILLE, Fla., Sept. 30, 2024 /PRNewswire/ -- Johnson & Johnson§, a global leader in eye health, has announced it's expanding the roll-out of its latest advancement in presbyopia ...